Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 14 min ago
Peer-reviewedCC BY-NC 4.0The European Journal of Public Health

Public health impact of influenza vaccination in adults ≥65 in Portugal, 2022–2025

  • I Kislaya
  • S Pereira da Silva
  • V Gómez
  • N Verdasca
  • AP Rodrigues
  • R Guiomar
  • A Machado
Read full textPDFDOICite

Abstract

Background: Vaccination is a primary preventive strategy to reduce influenza morbidity and mortality. Assessing how influenza vaccine effectiveness translates into real‑world reductions in severe outcomes in vulnerable populations is essential for public health decision‑making. This study aimed to estimate the impact of the influenza vaccination program in Portugal on influenza-related hospitalizations in ≥ 65 years old population during the 2022/23-2024/25 seasons.

Methods: Using data on influenza surveillance, hospitalizations, vaccine coverage, and vaccine effectiveness, we estimated the number of averted events (NAE), the prevention fraction (PF), and the number needed to vaccinate to prevent one hospitalization (NVN) per season in the population aged ≥65 years. Monte Carlo simulations were used to estimate the 95% uncertainty intervals of all impact parameters.

Results: Influenza vaccine effectiveness varied across seasons from 32% to 45%, depending on the circulating strain. Vaccine coverage ranged from 66% to 73%. In 2022/23, with predominant A(H3N2) circulation, vaccination averted 68 (95%UI 31.5-107.0) hospitalizations per 100000 inhabitants, corresponding to PF of 23.4% (95%UI 12.4-32.4) and NNV of 974 (95%CI 682-2310). In 2023/24, with A(H1N1)pdm09 predominance, NAE was 69.8 (95%UI 38.8-102.1) hospitalizations per 100000, PF 23.7% (95%UI 14.8-21.3), and NNV 945 (95%UI 646-1700). In 2024/25, with co-circulation of A(H3N2) and B/Victoria, we observed a higher NAE of 95.7 (95%UI 50.9-140.4) per 100000, with PF of 31.5% (95%UI 19.7-40.3) and NNV of 731 (95%UI 498-1373).

Conclusions: The seasonal influenza vaccination provided consistent benefits in adults aged ≥65, preventing a significant number of hospitalizations even in seasons with moderate vaccine effectiveness. Our findings support public health communication aimed at increasing vaccination coverage in Portugal and mitigating the impact of influenza epidemics on population health and the healthcare system.

Key messages: • Vaccination averted 68–95.7 influenza-related hospitalizations per 100000 adults ≥65 years annually, with one hospitalization prevented per 731–974 individuals vaccinated.

• Estimates of NAE and NNV reinforce the public health value of seasonal immunization programs and enhance public communication.

Related

  1. Reconstructing Dengue Exposure Dynamics and Assessing the Public Health Impact of Vaccination Scenarios Using Mathematical Models in Brazil
    Y. Ko, C. Santos, A. T. Huang +3
    medRxivPreprintCC BYFull textEpidemiology & public healthmedRxiv
  2. Estimating the Direct Impact of Influenza Vaccination and Vaccine-Averted Illnesses Using an Extended Static Compartmental Model
    Y. M. Yoo, A. N. Chard, J. H. Jara +5
    medRxivPreprintCC0Full textInfectious diseasemedRxiv
  3. Potential impact of changes in influenza vaccination coverage and effectiveness on pediatric influenza burden in the United States, 2022/23-2024/25
    S. E. Morris, S. M. Mathis, J. R. Chung +13
    medRxivPreprintCC0Full textEpidemiology & public healthmedRxiv
  4. Temporal trends and public health interventions shaping STI notifications in Portugal, 2014–2023
    MD Silva, PL Ramos, M Severo +2
    The European Journal of Public HealthPeer-reviewedCC BY-NC 4.0Full textInfectious diseasePMCEurope PMC
  5. Prevalence and factors influencing influenza vaccination among health care workers in China: a systematic review and meta-analysis.
    Lina Xiong, Chunfang Cheng, Jie Yun
    Frontiers in public healthPeer-reviewedCC BYFull textEpidemiology & public healthEurope PMC

Cite

BibTeXRIS
BibTeX
@article{kislaya2026public,
  title = {{Public health impact of influenza vaccination in adults ≥65 in Portugal, 2022–2025}},
  author = {I Kislaya and S Pereira da Silva and V Gómez and N Verdasca and AP Rodrigues and R Guiomar and A Machado},
  journal = {The European Journal of Public Health},
  year = {2026},
  month = oct,
  doi = {10.1093/eurpub/ckag169.174},
  url = {https://doi.org/10.1093/eurpub/ckag169.174},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - Public health impact of influenza vaccination in adults ≥65 in Portugal, 2022–2025
AU  - I Kislaya
AU  - S Pereira da Silva
AU  - V Gómez
AU  - N Verdasca
AU  - AP Rodrigues
AU  - R Guiomar
AU  - A Machado
PY  - 2026
DA  - 2026/10/01
JO  - The European Journal of Public Health
DO  - 10.1093/eurpub/ckag169.174
UR  - https://doi.org/10.1093/eurpub/ckag169.174
AB  - Background: Vaccination is a primary preventive strategy to reduce influenza morbidity and mortality. Assessing how influenza vaccine effectiveness translates into real‑world reductions in severe outcomes in vulnerable populations is essential for public health decision‑making. This study aimed to estimate the impact of the influenza vaccination program in Portugal on influenza-related hospitalizations in ≥ 65 years old population during the 2022/23-2024/25 seasons.  Methods: Using data on influenza surveillance, hospitalizations, vaccine coverage, and vaccine effectiveness, we estimated the number of averted events (NAE), the prevention fraction (PF), and the number needed to vaccinate to prevent one hospitalization (NVN) per season in the population aged ≥65 years. Monte Carlo simulations were used to estimate the 95% uncertainty intervals of all impact parameters.  Results: Influenza vaccine effectiveness varied across seasons from 32% to 45%, depending on the circulating strain. Vaccine coverage ranged from 66% to 73%. In 2022/23, with predominant A(H3N2) circulation, vaccination averted 68 (95%UI 31.5-107.0) hospitalizations per 100000 inhabitants, corresponding to PF of 23.4% (95%UI 12.4-32.4) and NNV of 974 (95%CI 682-2310). In 2023/24, with A(H1N1)pdm09 predominance, NAE was 69.8 (95%UI 38.8-102.1) hospitalizations per 100000, PF 23.7% (95%UI 14.8-21.3), and NNV 945 (95%UI 646-1700). In 2024/25, with co-circulation of A(H3N2) and B/Victoria, we observed a higher NAE of 95.7 (95%UI 50.9-140.4) per 100000, with PF of 31.5% (95%UI 19.7-40.3) and NNV of 731 (95%UI 498-1373).  Conclusions: The seasonal influenza vaccination provided consistent benefits in adults aged ≥65, preventing a significant number of hospitalizations even in seasons with moderate vaccine effectiveness. Our findings support public health communication aimed at increasing vaccination coverage in Portugal and mitigating the impact of influenza epidemics on population health and the healthcare system.  Key messages: • Vaccination averted 68–95.7 influenza-related hospitalizations per 100000 adults ≥65 years annually, with one hospitalization prevented per 731–974 individuals vaccinated.  • Estimates of NAE and NNV reinforce the public health value of seasonal immunization programs and enhance public communication.
SN  - 1101-1262
SN  - 1464-360X
ER  -